\ \ \ \ is the first-line pharmacological treatment for adolescents with major depressive disorder. - MP NHM CHO-2024 (Shift-1)

MP NHM CHO-2024 (Shift-1)

Mental Health Nursing (E5)

Easy

Appeared in: MP NHM CHO-2024 (Shift-1)

Explanation

Selective serotonin reuptake inhibitors (SSRIs) are the established first-line pharmacological treatment for major depressive disorder in adolescents due to their favorable safety and tolerability profile compared to other classes of antidepressants.
Both Fluoxetine and Escitalopram are specific SSRIs with FDA approval for use in adolescents, confirming that this class is the standard of care.
In a multiple-choice question where correct specific examples (Fluoxetine, Escitalopram) and their correct general class (SSRIs) are options, the general class is the most comprehensive and appropriate answer.

Option A: Venlafaxine is a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), not an SSRI. It is considered a second or third-line agent for adolescent depression due to a higher side-effect profile and lack of superior efficacy.
Option C: While Fluoxetine is a correct example of a first-line treatment, it is not the best answer because 'Selective serotonin reuptake inhibitors (SSRIs)' is a broader category that correctly encompasses all first-line options.
Option D: While Escitalopram is a correct example of a first-line treatment, it is not the best answer because 'Selective serotonin reuptake inhibitors (SSRIs)' is a broader category that correctly encompasses all first-line options.

Visual 1: Infographic: 'Key Antidepressant Classes for Adolescent MDD' comparing the mechanisms, key examples, and clinical pearls for SSRIs, SNRIs, TCAs, and MAOIs.
Visual 2: Flowchart: 'Treatment Algorithm for Adolescent Depression' illustrating the stepped-care approach, starting with psychotherapy and/or SSRIs as first-line treatment, and subsequent steps for non-response.

Clinical Relevance

Nursing practice connection: Knowing First-line pharmacotherapy for adolescent major depressive disorder helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
The nurse's primary role involves monitoring for the FDA's black box warning of increased risk of suicidal thinking and behavior in adolescents starting antidepressants. This requires vigilant assessment and patient education.
Patient and family education is critical. Nurses must explain that therapeutic effects can take several weeks to appear, which helps manage expectations and promote medication adherence.
What if the adolescent patient does not respond to an initial 8-week trial of an SSRI? The next step is typically to switch to another SSRI. If there is still no response, a switch to a different class, such as an SNRI like venlafaxine, may be considered, often in consultation with a child and adolescent psychiatrist.

How to Approach the Question

First, identify the key components of the question: 'first-line treatment', 'adolescents', and 'major depressive disorder'.
Next, analyze the options provided. Recognize that 'Fluoxetine' and 'Escitalopram' are specific drugs, while 'Selective serotonin reuptake inhibitors (SSRIs)' is a drug class, and 'Venlafaxine' belongs to a different class (SNRIs).
Recall or deduce the standard of care for this condition. Clinical guidelines establish SSRIs as the first-line choice.
Apply the test-taking strategy for hierarchical options: When a question includes several correct items at different levels of specificity (i.e., specific examples and the general category they belong to), the most encompassing correct category is the best answer.
Eliminate Venlafaxine as it is not a first-line agent. Conclude that SSRIs is the most appropriate answer over the specific examples of Fluoxetine and Escitalopram.

Concept Tested & Keywords

Concept Tested: First-line pharmacotherapy for adolescent major depressive disorder.
Stem keywords: first-line, pharmacological treatment, adolescents, major depressive disorder
Lead-in keywords: is

QW1jbOF2J5i4ccTokv7zos